The results of Protocol V provide the framework for a treatment strategy of patients in clinical practice with center-involved diabetic macular edema and good vision, according to a speaker.
“Ultimately, the framework here is an observe-and-extend, as opposed to a treat-and-extend,” Vaidehi S. Dedania, MD, said at the virtual OSN New York Retina meeting.
The DRCR Retina Network Protocol V evaluated treatment for center-involved diabetic macular edema (DME) in eyes with visual acuity of 20/25 or better. The randomized clinical trial evaluated Eylea (aflibercept, Regeneron) vs. laser
Uncategorized